Silence Therapeutics plc

Regulatory Filings • Dec 17, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0664X

Silence Therapeutics PLC

17 December 2019

DIRECTOR DISCLOSURE

17 December, 2019

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that the Company has been notified that David Horn Solomon, the Company's CEO, is subject to a private creditor action in Denmark arising as a result of his time as Managing Partner of Sund Capital, ApS from 2016 - 2018. Whilst this is a personal matter, entirely unrelated to Silence, a bankruptcy motion has been filed against David in Denmark which is due to be heard by the courts in the next few days. David is keeping the Silence Board closely informed on developments in relation to this matter and is confident that in time he can meet his financial obligations. David remains CEO of Silence.  

Enquiries:

Silence Therapeutics plc Iain Ross, Chairman	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray [email protected]	Tel: +44 (0) 20 3709 5700
US IR Westwicke Partners Peter Vozzo [email protected]	Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCEAFAKFLFNFAF